Treatment of Electrical Storm with Amiodarone in Brugada Syndrome- an Unexpected Protective Effect by Novak, J & Lambiase, PD
Case Report Open Access
Genetic Syndromes & Gene Therapy
Novak and Lambiase, J Genet Syndr Gene Ther 2013, 4:8
http://dx.doi.org/10.4172/2157-7412.1000176
Volume 4 • Issue 8 • 1000176
J Genet Syndr Gene Ther
ISSN: 2157-7412 JGSGT, an open access journal   Genetic Disorders
Keywords: Brugada syndrome; Genetic disorders
Case
A 53 year old man with a history of EEG proven epilepsy on 
treatment with Levetiracetam was successfully resuscitated from 
cardiac arrest due to polymorphic VT in January 2013. Resting ECG 
shows RBBB pattern. Ajmaline challenge testing induced typical 
type I coved ST elevation in V1-3 diagnostic of Brugada Syndrome 
with polymorphic VE’s and couplets (Figure 1). Cardiac magnetic 
resonance imaging revealed only a slightly hypokinetic apex consistent 
with post cardiac arrest changes with normal right & left ventricular 
size and function, no late enhancement/fat infiltration. A single 
chamber, BSCI Incepta Internal Cardiac Defibrillator (ICD) was 
implanted. Defibrillation testing achieved successful termination of 
induced Ventricular Fibrillation 10 J below maximum energy. The ICD 
was programmed to VVI mode back-up pacing 30 bpm, VF therapy 
Zone with shock and ATP during charging above 220/min and patient 
discharged home on Levetiracetam. 
Two days later the patient was admitted to his local hospital with 
9 appropriate ICD shocks- stored EGMs confirmed sudden onset 
polymorphic tachycardia mainly at 250-310 bpm terminated with 41 
J shock (Figure 2). Amiodarone was commenced in his local hospital, 
pacing was reprogrammed to VVI 90 bpm and the patient was 
discharged. Since amiodarone is reported to be pro-arrythmogenic in 
patients having Brugada syndrome [1-3], we elected to stop amiodarone 
2 weeks subsequently and replace this with Quinidine to protect the 
patient against further episodes of arrhythmia. 
The patient was admitted for the initiation of Quinidine, having 
stopped amiodarone for 2 days. The device check revealed that since 
stopping amiodarone the day prior to admission there has been 13 
episodes of NSVT, longest 11 beats, which all were self terminating, 
no therapies delivered. These episodes were all triggered by closely 
coupled premature ventricular beats. As amiodarone appeared to be 
successfully suppressing VT, it was restarted (200 mg once a day) and 
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Abstract
We are reporting on a 53 year old man with proven Brugada syndrome and ICD implantation for resuscitation 
in context of polymorphic VT. After recurrent arrhythmia he was treated with Amiodarone. This showed to have a 
protective effect despite various reports suggesting avoiding Amiodarone in Brugada syndrome.
A. Resting ECG B. Response to Ajmaline
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Figure 1A: Resting ECG on presentation-showing right bundle branch 
block pattern in leads V1-V3. B: Response to ajmaline challenge. Coved ST 
elevation standard leads V1 & V2 as well as high chest leads in 3rd intercostal 
space.
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Figure 2: ICD Electrogram traces of 3 VF Events. Triggering ventricular 
ectopics trigger VF at critically timed intervals. The ectopics are highlighted 
by an arrow.Citation: Novak J, Lambiase PD (2013) Treatment of Electrical Storm with Amiodarone in Brugada Syndrome- an Unexpected Protective Effect. J 
Genet Syndr Gene Ther 4: 176. doi:10.4172/2157-7412.1000176
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hypotheses repectively [5]. According to the repolarisation hypothesis, 
in contrast to endocardium, the epicardial action potential (AP) has a 
prominent phase 1 resulting in a spike and dome morphology (Figure 
3). This is thought to be the result of a more pronounced expression 
of the transient outward potassium channel (ITO) in epicardial cells, 
largely responsible for the rapid downstroke of phase 1. If, for any 
reason there is a reduction in the amplitude of phase 0, this will result in 
a lower voltage level at which phase 1 begins. This affects the activation/
inactivation kinetics of both ITO and the availability of the L-type 
calcium channel involved in the phase 2 plateau, resulting in a loss of 
the AP dome and consequent shortening of the epicardial AP duration 
(APD). The less pronounced phase 1 downstroke of endocardium due 
to lower ITO expression allows for conservation of the AP pattern, even 
with some reduction in phase 0 amplitude. The transmural gradient 
during phase 1 between the epicardium and endocardium was shown in 
the canine wedge experiments by Antzelevitch and Yan, to contribute 
to both J point and ST elevation on the surface ECG [6]. 
The depolarisation hypothesis proposes that coved ST elevation 
develops as a result of delays in conduction between the right ventricular 
body and outflow tract (RVOT). If the RVOT action potential is 
delayed in relation to that of the RV body, a voltage gradient develops 
between the two sites with the more positive membrane potential in the 
RV body (source) driving intercellular current to the RVOT (sink). The 
circuit is completed by extracellular current from the RVOT to the RV, 
inscribing a positive deflection on the ECG (J point and ST elevation). 
Conduction delays in the RVOT have been demonstrated in a number 
of human studies in BrS to support this hypothesis [7,8]. 
initially the base rate programmed to ventricular pacing (VVI) 80 beats/
min and the patient discharged. On subsequent follow-ups over the 
next month the device checks showed no arrhythmia despite marked 
coved ST elevation+ during treatment on resting ECG and the base 
pacing rate was reduced to 45 bpm. The patient continued on treatment 
with Amiodarone 200 mg od. Despite previous reports indicating that 
Amiodarone should be avoided in Brugada Syndrome this patient was 
successfully treated to prevent episodes of ventricular arrhythmia with 
this drug.
Discussion
Background 
Brugada syndrome is characterised by coved-type ST-segment 
elevation followed by a negative T-wave in right precordial leads 
V1-V3 (type 1 ECG pattern) or saddleback pattern in V1 (with ST-
segment elevation) or V2 (without ST-segment elevation), in addition 
to either documented ventricular fibrillation, polymorphic ventricular 
tachycardia, family history of sudden cardiac death aged <45 years, 
coved-type ECG changes in family members, inducibility of VT with 
programmed electrical stimulation, syncope or nocturnal agonal 
respiration. The estimated prevalence is 1/2000 in Caucasians although 
it may be greater in individuals of Asian descent. 
It is inherited in an autosomal dominant mode of transmission, 
with several possible genotypes identified coding calcium channels 
(CACNA1C, CACNB2b, CACNA2D1) resulting in loss of function of 
basal L-type calcium current (ICa,L), sodium channels leading to loss of 
function of INa (SCN1B, SCN3B) as well gain of function of potassium 
currents (KCNE3, KCND3,KCNE5). To date, mutations in at least 6 
distinct susceptibility genes have been identified (Table 1). The most 
common being mutations in the SCN5A gene (15-30% cases). 
A vast number of mutations (>100 known, missense mutations, 
nonsense mutation, nucleotide insertion/deletion and splice site 
mutation) occurring in the SCN5A gene account for roughly 30 % of 
all patients, coding the alpha subunit of subunit of the cardiac sodium 
channel, representing the commonest mutation in Brugada syndrome. 
It causes loss of function of the sodium channel (decreased expression 
of Nav1.5 proteins in sarcolemma and expression of non-functional 
or altered channels diminishing fast upstroke (Phase 0) of the action 
potential) leading to slowing of conduction (delayed activation, earlier 
or faster inactivation, enhanced slow inactivation and delayed recovery 
from inactivation). As these channels play a key role in electrical 
cardiac function SCN5A mutations not only cause Brugada syndrome 
but there is a significant overlap to other electrical or structural cardiac 
diseases (Long QT syndrome type 3, progressive cardiac conduction 
disease, sick sinus syndrome, atrial fibrillation, atrial standstill or dilated 
cardiomyopathy) [4]. Genetic testing is useful especially in context of 
family screening in case the index patient is gene positive. In this case 
there is no remarkable family history of SCD, unfortunately until now 
the family refused to undergo further functional or genetic testing. As 
the diagnosis was clear in this patient and family screening is currently 
not an option, gene testing has not been carried out. Yet as this patient 
showed a remarkable and unexpected response to Amiodarone in 
context of obvious Brugada syndrome blood has been taken during 
follow up for gene sequencing, still these results were pending when 
this article has been published, thus we will report and discuss these 
results separately in an addendum as soon as genes are available.
This mechanism of coved ST elevation on the ECG is debated with 
2 hypotheses having been proposed-the repolarisation & depolarisation 
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Figure 3: Repolarisation Hypothesis. Illustration of the proposed epicardial 
and endocardial electrogram morphologies creating the voltage gradients 
forming the coved ST elevation typical of the type 1 Brugada ECG.
Table 1: Genes Responsible for Brugada Syndrome.
Brugada 
syndrome
SCN5A
GPD1L
CACNA1C
CACNB2B SCN1B
KCNE3
SCN3B
HCN4
INa sodium channel α-subunit
Glycerol-3-phosphate dehydrogenase 1 like
ICa,L calcium channel α-subunit
ICa,L calcium channel β-subunit
INa sodium channel beta-1 subunit 
Ito voltage-gated potassium channel, Isk-related family
INa sodium channel type III beta
If hyperpolarization-activated potassium channel 4Citation: Novak J, Lambiase PD (2013) Treatment of Electrical Storm with Amiodarone in Brugada Syndrome- an Unexpected Protective Effect. J 
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Mechanism of VF
In this case, VF was consistently initiated by a closely coupled 
premature ventricular contraction (PVC). 
VF in Brugada Syndrome is thought to be initated by phase 2 re-
entry in the RVOT [9,10]. Previous studies (mainly experimental) 
suggested that in patients with Brugada syndrome the large transmural 
repolarisation gradient in the RVOT facilitates current flow during 
phase 2 of the action potential from the endoicardium to epicardial 
layers-hence the phenomenon of phase 2 re-entry due to the difference 
in repolarisation times between the mayocardial layers in the RVOT. 
The initiation of VF is illustrated on the ICD tracings which show 
the triggering beats repeatedly occurred at a coupling interval (CI) of 
240 ms. Recent studies of Brugada syndrome demonstrated that the CI 
of the triggered PVC of VF was within the range of 336-453 ms and the 
onset of the PVC was close to the end of T wave of the preceding beat 
which is consistent with the timing of phase 2 re-entry triggering beats 
[11,12]. Nam also reported that the CI of a triggered beat in patients 
with early repolarisation J point elevation pattern on ECG tended to 
be shorter than that seen in patients with Brugada syndrome [10]. In 
addition, Viskin et al. reported that the CI of a triggered beat was302 ± 
52 ms in 22 patients with idiopathic VF. In our patient, the triggering 
beats tended to be shorter and similar to the short-coupling variant 
form of idiopathic VF as opposed to the later PVC’s reported in BrS 
[13]. 
Amiodarone in brugada syndrome 
Amiodarone is predominantly a potassium ion channel–blocking 
agent (Vaughan Williams class III) but has been shown in vitro to 
have sodium ion channel–blocking properties, especially in the acute 
phase of its administration [14,15]. There have been limited case 
reports in the literature demonstrating how amiodarone can unmask 
the Brugada ECG and trigger ventricular arrhythmia presumably by 
enhancing the Na channel blocking effect in ion channel mutation 
carriers. What is unusual in this case is the fact that although the 
amiodarone promoted the type 1 ECG changes of Brugada Syndrome 
directly affecting the substrate, it suppressed the ventricular ectopic 
triggers leading to VF. The fact the PVCs were early coupled beats 
would suggest that the alternative anti-arrhythmic actions of the agent 
were preventing triggered activity as opposed to phase 2 re-entry. 
Since amiodarone significantly prolongs action potential during and 
increases refractoriness, it is conceivable that even if phase 2 re-entry 
were initiated the myocardium was too refractory to perpetuate it, since 
the patient had an ICD in situ, he had adequate protection to cardiovert 
VF should it occur. Utilisation of amiodarone for the purpose of 
suppressing VF in this circumstance should not be considered first 
line but given its efficacy in this case, it would suggest it may have a 
role in certain cirumstances e.g. When quinidine the ITo channel 
blocker recognised to suppress VF storm in Brugada Syndrome is 
not available or contraindicated due to side effects (liver dysfunction, 
blood dyscrasia). There is an emerging role of utilisation of epicardial 
ablation to modify the substrate in cases of VF storm due to Brugada 
syndrome which may evolve as the first line therapy in recurrent VF 
cases as opposed to pharmacological suppression depending upon its 
long term success and applicability [16]. 
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